Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Zoetis

Is Zoetis a Smart Investment in the Pharmaceuticals Sector?

Zoetis (ZTS) reported strong financial results for the last reported quarter. Amid the growing attention and concern on animal health and care, ZTS’ diverse product portfolio stands to benefit significantly from its continuous product innovations. So, should you buy this innovative pharmaceutical stock considering the current trends? Read more to…

StockNews.com

Zoetis Stock: Is ZTS Underperforming the Healthcare Sector?

Zoetis has recently underperformed the broader healthcare sector, but analysts remain optimistic about its long-term growth prospects.

Barchart

Is Zoetis Leading the Charge in Animal Health Innovation?

Zoetis Inc. (ZTS) reported impressive results for the third quarter of 2024, with strong revenue growth across diverse regions. The company’s future growth prospects appears promising, fueled by solid demand for its product offerings, operational expansions, and effective capital allocation. So, let’s determine whether Zoetis is an ideal addition to…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 'Strong Buy' Cyclical Stocks to Scoop Up Now

Brokerage firm Morgan Stanley is bullish on cyclical stocks.

Barchart

What Are Wall Street Analysts' Target Price for Zoetis Stock?

Zoetis has significantly underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

Barchart

Zoetis' Q3 2024 Earnings: What to Expect

Zoetis will release its third-quarter earnings next month, and analysts expect a single-digit profit surge.

Barchart

Zoetis's Q3 2024 Earnings: What to Expect

Zoetis will release its third-quarter earnings next month, and analysts expect a single-digit profit surge.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Defensive Dividend Stocks to Protect Against Pre-Election Volatility

As the U.S. presidential election nears, here are three defensive dividend-paying stocks to help shield your portfolio from pre-election volatility.

Barchart

Is Zoetis Stock Underperforming the Dow?

Despite Zoetis’s underperformance relative to the Dow Jones Industrials Average over the past year, Wall Street analysts remain optimistic about the stock’s prospects.

Barchart

Should You Buy Zoetis Amid Rising Pet Care Demand?

Zoetis (ZTS) continues to showcase its solid market position and commitment to innovation across its diverse portfolio, introducing advanced products that meet the evolving needs of animal health. Given its robust fundamentals and industry leadership, let’s find out if ZTS is a solid choice for those looking to invest in…

StockNews.com

Zoetis Stock: Is Wall Street Bullish or Bearish?

Despite Zoetis lagging behind the broader market over the past year, analysts still remain strongly bullish on the stock’s prospects.

Barchart

Zoetis Earnings Preview: What to Expect

As Zoetis is all set to announce its second-quarter earnings next month, analysts project a single-digit improvement in its bottom line.

Barchart

3 Pet Care Stocks to Watch

The pet care industry’s robust expansion is driven by rising disposable income, adoption of e-commerce platforms, and rising pet ownership. Therefore, investors could consider watching fundamentally sound pet care stocks, Zoetis (ZTS), IDEXX Laboratories (IDXX), and Chewy (CHWY). Keep reading.

StockNews.com

3 Top-Rated Healthcare Stocks With 20% to 35% Upside Potential

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Pharmaceutical Stocks With Blockbuster Potential

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….

Barchart

Is Zoetis Stock Underperforming the Nasdaq?

Despite Zoetis significantly trailing behind the Nasdaq Composite over the past three months, analysts seem extremely bullish on the stock’s prospects due to its robust product pipeline and global reach.

Barchart

3 'Strong Buy' Value Stocks to Buy and Hold

In today's uncertain economic landscape, marked by high inflation, high rates, and global uncertainty, here are three resilient 'Strong Buy' dividend stocks that investors can consider for long-term returns.

Fortune

The CFOs of Prudential, TD Securities, and Zoetis on how their roles have evolved: ‘You’re in the middle of everything’

At the Fortune Future of Finance conference, the leaders discussed the key expectations for their positions.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

5 High-Quality Stock Picks from Goldman Sachs

If you're wondering where to invest in these uncertain times, Goldman Sachs has dropped some hints with their top five stock picks that might just weather the storm.

StockNews.com

How To Painlessly Put Together A Profitable POWR Pairs Trade

Using the POWR Ratings to power profits on a POWR Pairs trade in Zoetis (ZTS) and Air Products (APD).

AAP

Victoria seals deal worth up to $350m for old CSL site

The Victorian government has purchased the former CSL site in Melbourne's inner north and on-sold part of the land to an animal vaccine giant.

StockNews.com

Zoetis (ZTS): Analyzing Earnings for Potential Gains

Veterinary drugmaker Zoetis Inc. (ZTS) is all set to disclose its fiscal fourth-quarter earnings tomorrow. With the company boasting an impressive track record of consistently surpassing earnings expectations, would it be wise to acquire the shares of ZTS ahead of its earnings? Keep reading to find out….

Barchart

3 Buy-Rated Healthcare Dividend Stocks for Income Investors

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

Fortune

Management consultants can make great CEOs—but they have to get their hands dirty first

Some 47 Fortune 500 CEOs have spent time as management consultants but first took more junior roles.

Fortune

Zoetis's Wetteny Joseph—one of the few Black CFOs in the Fortune 500—began his journey to finance chief in Haiti

Joseph shares his personal journey, discusses why representation matters, and explains what specific steps landed him in the C-suite.

1 2 3

People

Donald Trump

186,971 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.